View Older Stories View More Recent Stories

Feb 23, 2022 08:40AM MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
Feb 23, 2022 06:45AM Merck Shares Environmental, Social & Governance Priorities and Strategy
Feb 18, 2022 01:00PM European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
Feb 16, 2022 06:45AM Merck (MRK) Appoints New Leadership for Human Health Business
Feb 16, 2022 06:45AM Merck Announces New Leadership for Human Health Business
Feb 14, 2022 05:04PM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
Feb 14, 2022 05:00PM LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Sta
Feb 14, 2022 06:45AM Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities
Feb 10, 2022 06:45AM Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Feb 9, 2022 05:00PM Merck (MRK) Announces Publication of Pivotal Phase 3 Data for KEYTRUDA in High-Risk Early-Stage Triple-Negative Breast Cancer
Feb 9, 2022 05:00PM Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
Feb 8, 2022 06:47AM Merck (MRK) and Ridgeback Supplied 3.1M Courses of Molnupiravir to the US
Feb 8, 2022 06:45AM Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
Feb 7, 2022 09:05AM MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth
Feb 4, 2022 06:45AM Merck to Participate in the Guggenheim Oncology Conference 2022
Feb 3, 2022 06:30AM Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
Jan 28, 2022 06:47AM Merck (MRK) and Ridgeback Report Molnupiravir Demonstrated Activity Against Omicron Variant in In Vitro Studies
Jan 28, 2022 06:45AM Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
Jan 27, 2022 06:49AM Merck (MRK) Announce EC Approves KEYTRUDA as Adjuvant Therapy for Certain Patients With RCC Following Surgery
Jan 27, 2022 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Jan 25, 2022 01:34PM Merck Announces Second-Quarter 2022 Dividend
Jan 24, 2022 06:45AM Merck (MRK) Announces FDA Issues CRL for gefapixant
Jan 24, 2022 06:45AM Merck Provides U.S. and Japan Regulatory Update for Gefapixant
Jan 20, 2022 06:51AM Merck (MRK) Announces Publication of Results of Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA
Jan 20, 2022 06:50AM Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
Jan 20, 2022 06:45AM Merck (MRK) Announces Frank Clyburn's Upcoming Resignation
Jan 20, 2022 06:45AM Frank Clyburn to Leave Merck
Jan 18, 2022 05:01PM Merck's (MRK) KEYTRUDA Significantly Improved OS Versus Placebo in Certain Patients With Advanced HCC Previously Treated With Sorafenib
Jan 18, 2022 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Jan 18, 2022 08:02AM Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among Veterinarians
Jan 18, 2022 06:45AM Merck (MRK), Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Jan 18, 2022 06:45AM Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Jan 10, 2022 08:31AM Gilead Sciences (GILD) Enters Clinical Collaboration with Merck (MRK) to Evaluate Trodelvy in Combination With KEYTRUDA
Jan 10, 2022 06:46AM Merck (MRK) Announces KEYTRUDA Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Reg
Jan 10, 2022 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Canc
Jan 7, 2022 04:30PM Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
Jan 7, 2022 05:52AM Absci Corporation (ABSI) Enters Research Collaboration with Merck (MRK)
Jan 5, 2022 06:30AM FDA Accepts Samsung Bioepis’ and Organon’s (OGN) sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Jan 5, 2022 06:30AM FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Jan 4, 2022 05:00PM Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 29, 2021 05:15PM MilliporeSigma Announces $136.7 Million U.S. Government Contract Award for New Lateral Flow Membrane Production Facility in Sheboygan, Wisconsin
Dec 27, 2021 06:47AM Merck's (MRK) KEYTRUDA Plus LENVIMA Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
Dec 27, 2021 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
Dec 27, 2021 05:38AM Merck (MRK) and Ridgeback Announce Molnupiravir Receives Special Approval for Emergency in Japan
Dec 24, 2021 06:45AM Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Dec 23, 2021 11:08AM Merck (MRK) , Ridgeback’s Molnupiravir Receives U.S. FDA EUA for Treatment of High-Risk Adults With Mild to Moderate COVID-19
Dec 23, 2021 11:08AM Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
Dec 22, 2021 06:00AM Merck (MRK) and Ridgeback Announce UK Order for Additional 1.75 Million Courses of Molnupiravir
Dec 22, 2021 06:00AM Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
Dec 17, 2021 07:00AM TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations
View More Recent Stories View Older Stories